Brain‐X is an open access journal publishing cutting-edge discoveries and technologies to provide insight into the brain, neuroscience, and neurology. We're interested in interdisciplinary studies utilizing approaches from mathematics, physics, chemistry, engineering, materials, and information science to help understand the brain.

Journal Metrics

  • 41%Acceptance rate
  • 29 days Submission to first decision
view all metrics

Brain-X APC Waiver

Read more to learn about the journal.

Articles

PERSPECTIVE
Open access

The application and challenges of brain‐computer interfaces in the medical industry

  •  1 July 2025

Graphical Abstract

The application and challenges of brain-computer interfaces in the medical industry Issue 3, 2025

Brain-computer interfaces (BCIs) aim to create a connection pathway for information exchange between the brain and devices with computing capabilities. The complexities of non-invasive BCIs and the implantation risks associated with invasive BCIs have confined these technologies to laboratory settings. A lack of foundational technologies of non-invasive and invasive BCIs, the signal processing challenges associated with BCIs, the key components of BCIs, and the compatibility of BCI software and hardware are challenges that need to be solved for BCI commercialization.

PERSPECTIVE
Open access

Synergizing DeepSeek's artificial intelligence innovations with brain–computer interfaces

  •  28 June 2025

Graphical Abstract

Synergizing DeepSeek's artificial intelligence innovations with brain–computer interfaces Issue 2, 2025

This perspective examines the synergy between DeepSeek, a leader in efficient, open-source artificial intelligence models, and next-generation brain–computer interface (BCI) technologies. Based on the advanced technology of DeepSeek, this study explores the fusion of large language models (LLMs) in the fields of BCI devices, electroencephalogram signal processing, and individual service, and deeply discusses the data safety and ethical issues that are inevitable with LLMs, providing unique insights into the path to democratizing neurotechnology.

RESEARCH ARTICLE
Open access

Licochalcone A selectively modulates mTORC1-TFEB to enhance autophagy and demonstrates neuroprotective effects in a mouse model of Parkinson's disease

  •  27 June 2025

Graphical Abstract

Licochalcone A selectively modulates mTORC1-TFEB to enhance autophagy and demonstrates neuroprotective effects in a mouse model of Parkinson's disease Issue 2, 2025

Licochalcone A, a flavonoid from licorice, promotes TFEB's nuclear translocation through a non-canonical mTORC1 pathway involving Rag C and exerts neuroprotective effects in a mouse model of Parkinson's disease.

REVIEW ARTICLE
Open access

Non-human primate models of Parkinson's disease: Decoding pathogenesis and advancing therapies

  •  24 June 2025

Graphical Abstract

Non-human primate models of Parkinson's disease: Decoding pathogenesis and advancing therapies Issue 2, 2025

Parkinson's disease ranks as the second most prevalent neurodegenerative disorder, and there is an urgent need for proper experimental models to enhance our understanding of this complex disease. Non-human primates exhibit various similarities to humans, particularly in terms of motor skills, cognitive functions, and the complexity of their neural architecture. Models of Parkinson's disease using non-human primates can help us to understand the pathogenesis of Parkinson's disease, advance current therapies, and develop new methods in neuroscience.

RESEARCH ARTICLE
Open access

Development of a plasma biomarker diagnostic model as a screening strategy for Alzheimer's disease in older inpatients

  •  28 May 2025

Graphical Abstract

Development of a plasma biomarker diagnostic model as a screening strategy for Alzheimer's disease in older inpatients Issue 2, 2025

Early diagnosis of Alzheimer's disease (AD) is a challenge because of the invasive nature of the lumbar puncture for cerebrospinal fluid and the high cost of positron emission tomography imaging barriers for their common use as biomarkers. This study aimed to evaluate the diagnostic potential of blood-based neuro-markers in this advanced age group using an ultra-sensitive Single Molecule Array (SiMoA) platform. This simplified diagnostic model may offers a feasible approach for AD screening in both clinical and community-based settings.

More articles
More articles
More articles

Latest news

Recent issues